Cáncer colorrectal

  1. Molina Villaverde, R.
  2. Jiménez Gordo, A.M.
  3. López Gómez, M.
  4. Álvarez-Mon Soto, M.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (II) Tumores digestivos

Serie: 12

Número: 32

Páginas: 1911-1918

Tipo: Artículo

DOI: 10.1016/J.MED.2017.04.012 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Introducción El cáncer colorrectal (CCR) es la segunda causa de muerte en el mundo por un tumor maligno. Hay casos tanto esporádicos como hereditarios. Se ha asociado a distintos factores ambientales, entre los que destaca una baja ingesta de fibra. Diagnóstico Los estudios de cribado con colonoscopia han de hacerse con regularidad, especialmente en los pacientes de alto riesgo. Tratamiento En la enfermedad localizada, la cirugía es el tratamiento de elección. En los estadios III, el tratamiento adyuvante con quimioterapia ha demostrado beneficio en la supervivencia. Los pacientes con estadio IV tienen opciones de curación si las metástasis pueden ser resecadas, con una supervivencia a 5 años cercana al 50%. Para el manejo de la enfermedad metastásica (estadio IV) se utilizan combinaciones de quimioterapia y fármacos biológicos.

Referencias bibliográficas

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
  • Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B. Colorectal cancer. Lancet. 2010;375(9719):1030-47.
  • Vargas AJ, Thompson PA. Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 2012;27(5):613-23.
  • Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenterol Clin North Am. 1996;25(4):717-35.
  • Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29):3839-48.
  • Balmana J, Castells A, Cervantes A. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21Suppl5:v78-v81.
  • Hindi MN, Lamarca LA, Feliu BJ. [Hereditary colorectal cancer]. Med Clin (Barc). 2012;138(5):220-3.
  • Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
  • Speights VO, Johnson MW, Stoltenberg PH, Rappaport ES, Helbert B, Riggs M. Colorectal cancer: current trends in initial clinical manifestations. South Med J. 1991;84(5):575-578.
  • Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20Suppl4:61-3.
  • Lacy A. Colon cancer: laparoscopic resection. Ann Oncol. 2005;16(2):88-92.
  • Saltz LB. Adjuvant therapy for colon cancer. Surg Oncol Clin N Am. 2010;19(4):819-27.
  • Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-51.
  • Vieitez JM, García-Carbonero R, Aparicio J, Feliu J, González-Flores E, Grande E, et al. Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. Clin Transl Oncol. 2011;13(11):798-804.
  • Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):346-53.
  • Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD. Short course preoperatory radiotherapy with inmediate surgery versus long course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2014;23(4):211-21.
  • Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderke D. ESMO consensus guidelines for the manage-ment of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-422.
  • Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6): 985-92.
  • López-Gómez M, Cejas P, Merino M, Fernández-Luengas D, Casado E, Feliu J. Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol. 2012;14(9):641-58.
  • Ruers T, Punt C, Van Coevorden F: Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non resecable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619-26.
  • Salgado M. Consenso ESMO 2015: manejo del cáncer colorrectal avanzado. Rev Cancer. 2016;30(1):115-21.
  • Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5(1):63.
  • Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C. Panitumumab combined with irinotecan for patients with KRAS wild type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2012. 2013;24(2):412-9.
  • Tabernero J, Van Cutsem E, Lakomy R, Prausovà J, Ruff P, Van Hazel GA. Aflibercept versus placebo in combination with flurouracil, leucovorin and irinotecan in the treatment of previously metastatic colorectall cancer: Prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50(2):320-31.
  • Tabernero J, Yoshino T, Cohn AL, Obermanova R, Bodoky G, García-Carbonero R. Ramucirumab versus placebo in combination with second line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first line therapy with bevacizumab, oxaliplatin and a fluoropyrimmidine (RAISE): a randomised, double-blin. Lancet Oncol. 2015;16(5):499-508.
  • Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo controlled phase 3 trial. Lancet. 2013;381:303-12.
  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, García-Carbonero R, Mizunuma N. Randomised trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-19.
  • Liu DM, Thakor AS, Baerlocher M. A review of conventional and drug eluting chemoembolization in the treatment of colorectal liver metasta-ses: principles and proof. Future Oncol. 2015;11:1421-28.
  • Hendilisz A, Van den Eynde M, Peeters M. Phase III trial comparing protracted intravenous fluoracil infusion alone or ytrium-90 resin microspheres radioembolization for liver limited metastatic colorectal cancer refractory for standard chemotherapy. J Clin Oncol. 2010;28:3687-94
  • Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD. Followup care, surveillance protocol and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465-70.
Fuente de los datos: Dialnet